Stocktoria

ROCKWELL MEDICAL, INC. RMTI

Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-18.33
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$69.3M-$5.3M$11.7M$37.0M
2024$101.5M-$480,000$17.5M$32.6M
2023$83.6M-$8.4M$8.7M$21.3M
2022$72.8M-$18.7M$4.1M$14.1M
2021$61.9M-$32.7M-$2.4M$2.5M
2020$62.2M-$30.9M$2.7M$34.2M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Hunter HeatherChief Operating Officer2026-03-14Tax withheld2,444$0.90
TIMMINS MEGAN C.See Remarks2026-03-14Tax withheld3,667$0.90
Neri JesseSVP and CFO2026-03-14Tax withheld2,444$0.90
Chole TimothySVP and CCO2026-03-14Tax withheld2,444$0.90
Strobeck MarkPresident and CEO2026-03-14Tax withheld7,333$0.90
Hunter HeatherChief Operating Officer2026-01-02Sell2,868$0.84
Neri JesseSVP and CFO2026-01-02Sell886$0.84
COOPER JOHN Gdirector2025-11-18Sell5,079$0.87

Why these scores methodology →

Piotroski F-score: 2/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -18.33 (distress)

  • Working capital / assets 0.5
  • Retained earnings / assets -7.052
  • EBIT / assets -0.082
  • Equity / liabilities 1.834

Source: SEC EDGAR filings · CIK 0001041024 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.